Compounded Semaglutide: Clinics & Pricing Guide

Compounded semaglutide refers to medication prepared by compounding pharmacies using the same active ingredient. The FDA reference file is explicit that compounded versions are not the same as generics and are not FDA-approved.

The reference notes that compounding of semaglutide expanded during official FDA drug shortages. It also states that semaglutide was removed from the shortage list in February 2025, which means the legal landscape is in flux and patients should verify current status before starting care.

Because compounded semaglutide is not FDA-approved, quality depends on the pharmacy. The reference specifically says patients should confirm the pharmacy is licensed and accredited, with PCAB accreditation as a useful quality checkpoint.

Clinics discussing compounded semaglutide still need to address the underlying semaglutide dosing logic, side effects, and follow-up expectations from branded label experience. Patients should ask how medication is sourced, how titration is handled, and how ongoing monitoring works.

The FDA reference estimates compounded semaglutide at roughly $200 to $500 per month, with wide variation across pharmacies and clinic programs.

That is typically cheaper than brand-name semaglutide, but prices vary by pharmacy and location and lower price does not remove sourcing or quality questions.

Prices vary by pharmacy, location, and clinic structure.

The main comparison is not just compounded versus brand-name price. It is FDA-approved branded semaglutide versus a non-FDA-approved compounded pathway where quality and legality may change over time.

That means the better clinic questions are about pharmacy sourcing, accreditation, follow-up, and whether a branded option like Wegovy makes more sense for your situation.